Literature DB >> 661926

Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda.

G H Elder, G B Lee, J A Tovey.   

Abstract

To investigate the role of uroporphyrinogen decarboxylase in the pathogenesis of the sporadic form of porphyria cutanea tarda, we measured this enzyme in liver, erythrocytes and cultured skin fibroblasts, and also measured coproporphyrinogen oxidase and the total iron concentration in liver. The mean uroporphyrinogen decarboxylase activity was lower in liver from seven male patients (9.0 pmol of coproporphyrin per minute per milligram of protein) than in 12 controls, including seven with alcoholic liver disease (22.3 pmol per minute per milligram; P less than 0.05). Coproporphyrinogen oxidase activities were the same in each group. Liver iron concentrations were lower during remission, but uroporphyrinogen decarboxylase activities were not related to clinical activity for uroporphyrin excretion. Erythrocyte and fibroblast enzyme activities were the same as in normal subjects. A hepatic uroporphyrinogen decarboxylase defect is a prerequisite for the development of porphyria cutanea tarda, but other factors, which probably do not alter uroporphyrinogen decarboxylase activity, determine the clinical onset. In sporadic porphyria cutaneous tarda, the enzyme defect appears to be restricted to the liver.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 661926     DOI: 10.1056/NEJM197808102990603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  23 in total

1.  Photosensitivity and lymphoma.

Authors:  D P Busuttil; M G Davies; J A Copplestone; M D Hamon; A G Prentice
Journal:  Postgrad Med J       Date:  1997-07       Impact factor: 2.401

2.  Crystal structure of human uroporphyrinogen decarboxylase.

Authors:  F G Whitby; J D Phillips; J P Kushner; C P Hill
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

3.  The genetic basis of porphyria cutanea tarda.

Authors:  R Enriquez de Salamanca; A Olmos; M L Peña; L Berges; J Perpiñá
Journal:  Arch Dermatol Res       Date:  1985       Impact factor: 3.017

4.  Enzymatic and immunological studies of uroporphyrinogen decarboxylase in familial porphyria cutanea tarda and hepatoerythropoietic porphyria.

Authors:  H de Verneuil; C Beaumont; J C Deybach; Y Nordmann; Z Sfar; R Kastally
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

5.  Assignment of the gene for uroporphyrinogen decarboxylase to human chromosome 1 by somatic cell hybridization and specific enzyme immunoassay.

Authors:  H de Verneuil; B Grandchamp; C Foubert; D Weil; V C N'Guyen; M S Gross; S Sassa; Y Nordmann
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

6.  Functional characterisation and transcriptional regulation of the KlHEM12 gene from Kluyveromyces lactis.

Authors:  Laura Núñez; Isabel González-Siso; Manuel Becerra; M Esperanza Cerdán
Journal:  Curr Genet       Date:  2004-07-15       Impact factor: 3.886

7.  Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles.

Authors:  M Mendez; L Sorkin; M V Rossetti; K H Astrin; A M del C Batlle; V E Parera; G Aizencang; R J Desnick
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

8.  [Influence of chloroquine on the hexachlorobenzene-induced porphyria. Investigations in the skin, liver, and urine (author's transl)].

Authors:  W Vizethum; K Bolsen; K Simon; K Weber; G Goerz
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

9.  Effects of polychlorinated biphenyl compounds, 2,3,7,8-tetrachlorodibenzo-p-dioxin, phenobarbital and iron on hepatic uroporphyrinogen decarboxylase. Implications for the pathogenesis of porphyria.

Authors:  H De Verneuil; S Sassa; A Kappas
Journal:  Biochem J       Date:  1983-07-15       Impact factor: 3.857

10.  Uroporphyrin I stimulation of collagen biosynthesis in human skin fibroblasts. A unique dark effect of porphyrin.

Authors:  G Varigos; J R Schiltz; D R Bickers
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.